Homepage
Medication Guide
What are the Indications of Futibatinib?
Futibatinib is an oral kinase inhibitor that was first approved for marketing in the United States in 2022. As a targeted therapy, it is mainly indicated for the treatment of advanced cholangiocarcino...
507
Wednesday, January 28th, 2026, 11:16
What Are the Purchase Channels for Futibatinib?
Futibatinib is a targeted drug indicated for the treatment of cholangiocarcinoma with specific genetic abnormalities. As a prescription medication, it must be used under the guidance of a physician. F...
504
Wednesday, January 28th, 2026, 11:14
Adverse Reactions of Eplerenone (Inspra)
Eplerenone (Inspra) is a selective aldosterone receptor antagonist, primarily indicated for the treatment of adult patients with heart failure following myocardial infarction, as well as adult hyperte...
504
Wednesday, January 28th, 2026, 10:41
What are the Precautions for Eplerenone (Inspra) Administration?
Eplerenone (Inspra) is a selective aldosterone receptor antagonist, primarily indicated to improve survival in adult patients with heart failure symptoms following acute myocardial infarction, as well...
506
Wednesday, January 28th, 2026, 10:07
Dosage and Administration of Eplerenone (Inspra)
Eplerenone (Inspra) is an aldosterone receptor antagonist. Clinically, it is mainly used to improve the survival rate of adult patients with symptomatic heart failure accompanied by reduced ejection f...
506
Tuesday, January 27th, 2026, 11:47
What are the Indications of Eplerenone (Inspra)?
Eplerenone (Inspra) is an oral aldosterone receptor antagonist. Since its first approval in the United States in 2002, it has played an important role in post-heart failure management and hypertension...
503
Tuesday, January 27th, 2026, 11:45
What Are the Purchase Channels for Eplerenone (Inspra)?
Eplerenone (Inspra) is an aldosterone receptor antagonist, mainly indicated for the treatment of patients with cardiac insufficiency following acute myocardial infarction, as well as the management of...
505
Tuesday, January 27th, 2026, 11:41
Adverse Reactions of Roflumilast Tablets (Daxas)
Roflumilast Tablets (Daxas) is a selective phosphodiesterase 4 (PDE4) inhibitor. It is indicated for patients with severe chronic obstructive pulmonary disease (COPD) who have a history of chronic bro...
506
Tuesday, January 27th, 2026, 11:38
What are the Precautions for Taking Roflumilast Tablets (Daxas)?
Roflumilast Tablets (Daxas) are a selective phosphodiesterase 4 inhibitor, primarily indicated for reducing the risk of acute exacerbations in patients with severe chronic obstructive pulmonary diseas...
501
Tuesday, January 27th, 2026, 11:35
Dosage and Administration, Recommended Dosage of Roflumilast Tablets (Daxas)
Roflumilast Tablets (Daxas) are a selective phosphodiesterase 4 (PDE4) inhibitor, primarily indicated for reducing the risk of acute exacerbations in patients with severe chronic obstructive pulmonary...
503
Monday, January 26th, 2026, 11:58
10 / 206
2051 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved